• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

提高蟾毒内酯溶解度和生物利用度的新策略。

Novel Strategies for Solubility and Bioavailability Enhancement of Bufadienolides.

机构信息

College of Pharmacy, Shandong University of Traditional Chinese Medicine, 4655 Daxue Road, Jinan 250355, China.

出版信息

Molecules. 2021 Dec 22;27(1):51. doi: 10.3390/molecules27010051.

DOI:10.3390/molecules27010051
PMID:35011278
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8746454/
Abstract

Toad venom contains a large number of bufadienolides, which have a variety of pharmacological activities, including antitumor, cardiovascular, anti-inflammatory, analgesic and immunomodulatory effects. The strong antitumor effect of bufadienolides has attracted considerable attention in recent years, but the clinical application of bufadienolides is limited due to their low solubility and poor bioavailability. In order to overcome these shortcomings, many strategies have been explored, such as structural modification, solid dispersion, cyclodextrin inclusion, microemulsion and nanodrug delivery systems, etc. In this review, we have tried to summarize the pharmacological activities and structure-activity relationship of bufadienolides. Furthermore, the strategies for solubility and bioavailability enhancement of bufadienolides also are discussed. This review can provide a basis for further study on bufadienolides.

摘要

蟾蜍毒液中含有大量的蟾毒配基,具有多种药理活性,包括抗肿瘤、心血管、抗炎、镇痛和免疫调节作用。蟾毒配基的强烈抗肿瘤作用近年来引起了相当大的关注,但由于其溶解度低和生物利用度差,蟾毒配基的临床应用受到限制。为了克服这些缺点,已经探索了许多策略,如结构修饰、固体分散体、环糊精包合、微乳液和纳米药物传递系统等。在这篇综述中,我们试图总结蟾毒配基的药理活性和构效关系。此外,还讨论了提高蟾毒配基溶解度和生物利用度的策略。这篇综述可以为进一步研究蟾毒配基提供依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c6b/8746454/e97c95b6ade1/molecules-27-00051-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c6b/8746454/28649e4d2210/molecules-27-00051-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c6b/8746454/b7b0a22abd5d/molecules-27-00051-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c6b/8746454/d3080028d1cc/molecules-27-00051-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c6b/8746454/cadd1293eec3/molecules-27-00051-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c6b/8746454/877a79a1395c/molecules-27-00051-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c6b/8746454/15d296ba83be/molecules-27-00051-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c6b/8746454/909420d2cbd6/molecules-27-00051-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c6b/8746454/1c62b5a36db1/molecules-27-00051-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c6b/8746454/8cdb1d711f81/molecules-27-00051-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c6b/8746454/7fcca8664d01/molecules-27-00051-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c6b/8746454/5df06d35703a/molecules-27-00051-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c6b/8746454/e97c95b6ade1/molecules-27-00051-g012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c6b/8746454/28649e4d2210/molecules-27-00051-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c6b/8746454/b7b0a22abd5d/molecules-27-00051-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c6b/8746454/d3080028d1cc/molecules-27-00051-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c6b/8746454/cadd1293eec3/molecules-27-00051-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c6b/8746454/877a79a1395c/molecules-27-00051-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c6b/8746454/15d296ba83be/molecules-27-00051-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c6b/8746454/909420d2cbd6/molecules-27-00051-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c6b/8746454/1c62b5a36db1/molecules-27-00051-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c6b/8746454/8cdb1d711f81/molecules-27-00051-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c6b/8746454/7fcca8664d01/molecules-27-00051-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c6b/8746454/5df06d35703a/molecules-27-00051-g011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c6b/8746454/e97c95b6ade1/molecules-27-00051-g012.jpg

相似文献

1
Novel Strategies for Solubility and Bioavailability Enhancement of Bufadienolides.提高蟾毒内酯溶解度和生物利用度的新策略。
Molecules. 2021 Dec 22;27(1):51. doi: 10.3390/molecules27010051.
2
Advances on Delivery System of Active Ingredients of Dried Toad Skin and Toad Venom.干蟾皮和蟾酥活性成分给药系统的研究进展。
Int J Nanomedicine. 2024 Jul 18;19:7273-7305. doi: 10.2147/IJN.S469742. eCollection 2024.
3
Toad venom bufadienolides and bufotoxins: An updated review.蟾蜍毒液中的蟾毒配基和蟾毒素:最新研究综述。
Drug Dev Res. 2023 Aug;84(5):815-838. doi: 10.1002/ddr.22072. Epub 2023 May 8.
4
Anti-tumor effects and 3D-quantitative structure-activity relationship analysis of bufadienolides from toad venom.蟾酥中蟾毒内酯的抗肿瘤作用及 3D 定量构效关系分析。
Fitoterapia. 2019 Apr;134:362-371. doi: 10.1016/j.fitote.2019.03.006. Epub 2019 Mar 12.
5
Chemical profiling and cytotoxicity assay of bufadienolides in toad venom and toad skin.蟾蜍毒液和蟾皮中蟾毒内酯的化学特征分析及细胞毒性检测。
J Ethnopharmacol. 2016 Jul 1;187:74-82. doi: 10.1016/j.jep.2016.03.062. Epub 2016 Apr 6.
6
Effect of drying methods on the free and conjugated bufadienolide content in toad venom determined by ultra-performance liquid chromatography-triple quadrupole mass spectrometry coupled with a pattern recognition approach.干燥方法对蟾酥中游离和结合型蟾蜍二烯羟酸内酯含量的影响:采用超高效液相色谱-三重四极杆质谱联用模式识别方法进行测定
J Pharm Biomed Anal. 2015 Oct 10;114:482-7. doi: 10.1016/j.jpba.2015.05.032. Epub 2015 Jul 15.
7
Bufadienolides from amphibians: A promising source of anticancer prototypes for radical innovation, apoptosis triggering and Na/K-ATPase inhibition.来自两栖动物的蟾蜍二烯羟酸内酯:用于彻底创新、触发细胞凋亡和抑制钠钾ATP酶的抗癌原型的一个有前景的来源。
Toxicon. 2017 Mar 1;127:63-76. doi: 10.1016/j.toxicon.2017.01.004. Epub 2017 Jan 7.
8
[Identification of bufadienolides profiling in cinobufacino by HPLC-DAD-FT-ICR-MS method].[采用高效液相色谱-二极管阵列检测-傅里叶变换离子回旋共振质谱法鉴定华蟾素中蟾毒配基的谱图]
Yao Xue Xue Bao. 2014 Feb;49(2):244-8.
9
Screening of Bufadienolides from Toad Venom Identifies Gammabufotalin as a Potential Anti-inflammatory Agent.从蟾蜍毒液中筛选蟾蜍毒内酯,鉴定出 γ- 蟾蜍毒它灵是一种有潜力的抗炎剂。
Planta Med. 2022 Jan;88(1):43-52. doi: 10.1055/a-1248-2626. Epub 2020 Oct 13.
10
Improved antitumor efficacy and reduced toxicity of liposomes containing bufadienolides.含蟾毒内酯脂质体的抗肿瘤疗效增强和毒性降低。
Arch Pharm Res. 2011 Sep;34(9):1487-94. doi: 10.1007/s12272-011-0910-9. Epub 2011 Oct 6.

引用本文的文献

1
Combinational Antitumor Strategies Based on the Active Ingredients of Toad Skin and Toad Venom.基于蟾皮和蟾毒液活性成分的联合抗肿瘤策略。
Drug Des Devel Ther. 2024 Aug 9;18:3549-3594. doi: 10.2147/DDDT.S469832. eCollection 2024.
2
Advances on Delivery System of Active Ingredients of Dried Toad Skin and Toad Venom.干蟾皮和蟾酥活性成分给药系统的研究进展。
Int J Nanomedicine. 2024 Jul 18;19:7273-7305. doi: 10.2147/IJN.S469742. eCollection 2024.
3
Pharmacological insights and role of bufalin (bufadienolides) in inflammation modulation: a narrative review.

本文引用的文献

1
19-Hydroxybufalin inhibits non-small cell lung cancer cell proliferation and promotes cell apoptosis via the Wnt/β-catenin pathway.19-羟基蟾毒灵通过Wnt/β-连环蛋白信号通路抑制非小细胞肺癌细胞增殖并促进细胞凋亡。
Exp Hematol Oncol. 2021 Oct 25;10(1):48. doi: 10.1186/s40164-021-00243-0.
2
Bufalin enhances the killing efficacy of NK cells against hepatocellular carcinoma by inhibiting MICA shedding.蟾毒灵通过抑制 MICA 的脱落增强 NK 细胞对肝癌的杀伤作用。
Int Immunopharmacol. 2021 Dec;101(Pt B):108195. doi: 10.1016/j.intimp.2021.108195. Epub 2021 Oct 19.
3
A network pharmacology approach to investigate the anticancer mechanism of cinobufagin against hepatocellular carcinoma via downregulation of EGFR-CDK2 signaling.
药理学研究与杠柳毒苷(蟾毒配基)在炎症调节中的作用:一篇综述。
Inflammopharmacology. 2024 Oct;32(5):3057-3077. doi: 10.1007/s10787-024-01517-9. Epub 2024 Jul 16.
4
Resibufogenin: An Emerging Therapeutic Compound with Multifaceted Pharmacological Effects - A Comprehensive Review.瑞布福新醇:一种具有多方面药理作用的新兴治疗化合物——全面综述。
Med Sci Monit. 2024 Feb 19;30:e942783. doi: 10.12659/MSM.942783.
5
An overview of the past decade of bufalin in the treatment of refractory and drug-resistant cancers: current status, challenges, and future perspectives.蟾毒灵治疗难治性和耐药性癌症的十年综述:现状、挑战及未来展望
Front Pharmacol. 2023 Oct 4;14:1274336. doi: 10.3389/fphar.2023.1274336. eCollection 2023.
6
Pharmacological Effects of Cinobufagin.华蟾素的药理学作用。
Med Sci Monit. 2023 Sep 25;29:e940889. doi: 10.12659/MSM.940889.
7
Toad venom-derived bufadienolides and their therapeutic application in prostate cancers: Current status and future directions.蟾蜍毒液来源的强心甾烯蟾毒类化合物及其在前列腺癌治疗中的应用:现状与未来方向
Front Chem. 2023 Mar 16;11:1137547. doi: 10.3389/fchem.2023.1137547. eCollection 2023.
8
Bioactive Compounds from Genus Potentially Useful for the Development of New Drugs.来自某属的生物活性化合物可能对新药开发有用。
Life (Basel). 2023 Feb 26;13(3):646. doi: 10.3390/life13030646.
9
Strategies for Solubility and Bioavailability Enhancement and Toxicity Reduction of Norcantharidin.去甲斑蝥素增溶、生物利用度提高和减毒策略。
Molecules. 2022 Nov 10;27(22):7740. doi: 10.3390/molecules27227740.
10
Uncovering the antimalarial potential of toad venoms through a bioassay-guided fractionation process.通过生物测定指导的分离过程揭示蟾蜍毒液的抗疟潜力。
Int J Parasitol Drugs Drug Resist. 2022 Dec;20:97-107. doi: 10.1016/j.ijpddr.2022.10.001. Epub 2022 Oct 14.
基于网络药理学探讨华蟾酥毒基通过下调 EGFR-CDK2 信号通路抗肝癌的作用机制。
Toxicol Appl Pharmacol. 2021 Nov 15;431:115739. doi: 10.1016/j.taap.2021.115739. Epub 2021 Oct 4.
4
Biomimetic nanoparticles loading with gamabutolin-indomethacin for chemo/photothermal therapy of cervical cancer and anti-inflammation.载姜黄素-吲哚美辛仿生纳米粒用于宫颈癌的化疗/光热治疗及抗炎
J Control Release. 2021 Nov 10;339:259-273. doi: 10.1016/j.jconrel.2021.09.034. Epub 2021 Sep 29.
5
Cytotoxic Effects of Hellebrigenin and Arenobufagin Against Human Breast Cancer Cells.嚏根草苷元和华蟾毒精对人乳腺癌细胞的细胞毒性作用
Front Oncol. 2021 Aug 26;11:711220. doi: 10.3389/fonc.2021.711220. eCollection 2021.
6
Bufalin suppresses tumour microenvironment-mediated angiogenesis by inhibiting the STAT3 signalling pathway.蟾毒灵通过抑制 STAT3 信号通路抑制肿瘤微环境介导的血管生成。
J Transl Med. 2021 Sep 8;19(1):383. doi: 10.1186/s12967-021-03058-z.
7
Co-delivery of bufalin and nintedanib via albumin sub-microspheres for synergistic cancer therapy.白蛋白亚微球共载巴氟啶和尼达尼布用于协同癌症治疗。
J Control Release. 2021 Oct 10;338:705-718. doi: 10.1016/j.jconrel.2021.08.049. Epub 2021 Sep 1.
8
Cinobufagin-induced DNA damage response activates G/M checkpoint and apoptosis to cause selective cytotoxicity in cancer cells.华蟾酥毒基诱导的DNA损伤反应激活G/M检查点和凋亡,从而对癌细胞产生选择性细胞毒性。
Cancer Cell Int. 2021 Aug 23;21(1):446. doi: 10.1186/s12935-021-02150-0.
9
Bufalin induces mitochondrial dysfunction and promotes apoptosis of glioma cells by regulating Annexin A2 and DRP1 protein expression.蟾毒灵通过调节膜联蛋白A2和动力相关蛋白1的蛋白表达诱导胶质瘤细胞的线粒体功能障碍并促进其凋亡。
Cancer Cell Int. 2021 Aug 10;21(1):424. doi: 10.1186/s12935-021-02137-x.
10
Effects of low-dose bufalin combined with hydroxycamptothecin on human castration-resistant prostate cancer xenografts in nude mice.低剂量蟾毒灵联合羟基喜树碱对裸鼠人去势抵抗性前列腺癌异种移植瘤的影响
Exp Ther Med. 2021 Sep;22(3):1015. doi: 10.3892/etm.2021.10447. Epub 2021 Jul 15.